Piramal Pharma Solutions: A globally integrated CDMO serving the pharmaceutical and biotech industries.

Piramal Pharma Solutions is the contract development and manufacturing organisation (CDMO) arm of Piramal Pharma Limited, offering end-to-end services across the drug lifecycle. With operations spanning North America, Europe, and Asia, the company supports innovator and generic pharmaceutical firms through a global network of development and manufacturing facilities. Its integrated model enables partners to reduce complexity, accelerate timelines, and enhance quality across both drug substance and drug product development and manufacturing.

Piramal Pharma Solutions stands out for its strong regulatory track record, a commitment to quality, and a long-standing focus on customer centricity. The company’s capabilities are tailored to meet the demands of small and large molecule programmes, with specialised expertise in handling highly potent APIs (HPAPIs), antibody-drug conjugates (ADCs), sterile injectable formulations, and complex oral solid dosage forms.

Key Products and Services:

• API services including early development, scale-up, and commercial manufacturing

• HPAPI development and manufacturing

• Antibody-drug conjugate (ADC) development

• Formulation development and manufacturing for oral solids and sterile injectables

• Integrated drug substance and drug product offerings

• Discovery services through Piramal’s collaboration-driven model

• Clinical trial supply and commercial supply chain solutions

Piramal Pharma Solutions’ development and manufacturing capabilities span 15 global facilities, each compliant with major regulatory authorities including the US FDA, UK MHRA, and EMA. The company supports over 400 clients worldwide and has successfully completed more than 120 commercial launches. With over 2,200 scientists and 1,400 regulatory filings, Piramal continues to position itself as a trusted partner for complex pharmaceutical development and manufacturing programmes.